UNIQUE BIOFILM TECHNOLOGY Wound Care – Oral Care - Disinfectants



Gord Froehlich President and CEO

TURNING NOVEL DISCOVERIES INTO INNOVATIVE HEALTH CARE SOLUTIONS




DispersinB® and Aledex® and StrixNB™ are trademarks of Kane Biotech Inc.

Forward-looking statements

This presentation contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the availability of funds and resources to pursue R&D activities, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in its specific industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's ongoing filings with the Canadian and U.S. securities authorities for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements nor does the Company undertake to update these forward-looking statements.



Unique Biofilm Technology



Biofilms – bacteria that form a slimy film Highly resistant to antibiotics, antimicrobials Cause tooth decay, infections and contaminations

Why customers want our technology

StrixNB: Oral Care = \$1 Billion Companion Animal, \$20 Billion Human

Breaks down plaque – tartar, prevention and treatment of periodontal disease and bad breath

<u>DispersinB:</u> Wound Care = \$4 Billion Atopic Dermatitis, \$4 Billion wound care


Prevents and disperses biofilms in dermatitis, acute and chronic wounds.

KBI Disinfectant: Hard Surface Disinfectant - = \$2.8 Billion

Controls antibiotic and biocide resistant biofilm embedded bacteria



Product Pipeline





Distribution and Licensing Strategy

Establish the Value Proposition

- Develop a portfolio of products
- Market test products
 - Formulations, messages, price, SOP
- Obtain veterinary support and endorsement
- Obtain consumer feedback
- First revenue stream





Animal Health Market

- Americans spent \$55.7 billion on pets in 2013
- Canadians spent \$6.5-billion on pets in 2013
- Market expected to grow
- 104 million cats and 86 million dogs in the United States and Canada





Unique Market Differentiation

- StrixNB Oral Care
 - LRVHP
 - no xylitol, chlorhexidine, or grain alcohol
 - Most effective antibiofilm oral care solution
- DispersinB Shampoo
 - Ingredients are gentle on skin
 - No salicylic acid, selenium sulfide, tar, sulfur, or ketoconazole
 - Most effective antibiofilm shampoo




StrixNB – Oral Care

Comparison of the effects of StrixNB on VSC levels in dogs

• Bad breath effect most noticeable on older dogs







DispersinB – Dermatology

DispersinB shampoo used once a week for 4 weeks on ferrets.

- · Substantial decrease in itchiness.
- Healing of wounds and improvement in quality of life.

BEFORE AFTER







Health Canada Approvals

Animal Health

- StrixNB water additive
- StrixNB powder
- StrixNB oral spray
- DispersinB topical spray
- DispersinB shampoo (pending)

Human Health

- DispersinB shampoo
- DispersinB wound care cream
- KBI disinfectant (antimicrobial claims)



Testimonials

- "StrixNB Water Additive has helped keep my shelties teeth clean and saved money on dental cleanings. As a breeder I have many dogs, so it isn't practical for me to brush their teeth." *Kerry Sheltie Breeder*
- "StrixNB Water Additive Powder is amazing, it peels plaque and tartar right off of my dogs' teeth." Chris Miniature Schnauzer Breeder
- "I have tried every medicated shampoo, treatments, and even antifungal oral medication...nothing had helped my 11 year old dog (suffering from a seborrheic dermatitis condition). DispersinB Shampoo has removed the scales, greatly reduced the inflammation and itchiness. Me and my dog appreciate it! " Sheila RAHT



Animal Health Portfolio





Kane Biotech Inc.
Gord Froehlich
President & CEO
162-196 Innovation Drive, R3T 2N2
Winnipeg, Manitoba, Canada

gfroehlich@kanebiotech.com www.kanebiotech.com

TSXV:KNE

